KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has ...

KalVista (KALV) announced that Japan’s Ministry of Health, Labour and Welfare, or MHLW, has granted sebetralstat orphan drug designation. The ...

CAMBRIDGE, Mass. & SALISBURY, England - KalVista Pharmaceuticals, Inc. (NASDAQ: NASDAQ:KALV) has received Orphan Drug ...

Fintel reports that on January 7, 2025, TD Cowen initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Buy recommendation. Analyst Price Forecast Suggests 224.00% Upside As of December ...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVista’s board of ...

Barclays PLC increased its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Free Report) by 418.5% during the third quarter, Holdings Channel.com reports. The fund owned 67,222 ...

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases ...

CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO).

January 16, 2025, 04:48 am ET, BY Robert S.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short KALV slightly ...

Fintel reports that on December 18, 2024, B of A Securities initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Buy recommendation. As of December 3, 2024, the average one-year ...

KalVista Pharmaceuticals, Inc. (KALV) announced Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...